2025年6月15日,强生公司公布了II期RedirecTT-1研究的最新数据,这是一项评估全球首个GPRC5D靶向双抗TALVEY®(talquetamab-tgvs)与首个BCMA靶向双抗TECVAYLI®(teclistamab-cqyv)的联合疗法的临床试验。结果显示,在三重暴露(TCE)复发/难治性多发性骨髓瘤(RRMM)伴真实髓外病变(EMD)患者中,该组合疗法实现高客观缓解率(ORR...
Source Link2025年6月15日,强生公司公布了II期RedirecTT-1研究的最新数据,这是一项评估全球首个GPRC5D靶向双抗TALVEY®(talquetamab-tgvs)与首个BCMA靶向双抗TECVAYLI®(teclistamab-cqyv)的联合疗法的临床试验。结果显示,在三重暴露(TCE)复发/难治性多发性骨髓瘤(RRMM)伴真实髓外病变(EMD)患者中,该组合疗法实现高客观缓解率(ORR...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.